Literature DB >> 14606981

A cross-sectional retrospective assessment of anti-arthritic drugs in patients with arthritis in Korea.

Myung Chul Lee1, Seokhyun Lee, Dong-Churl Suh, Jeeyeon Kim, Sheldon X Kong.   

Abstract

BACKGROUND: Selective cyclo-oxygenase-2 (COX-2) inhibitors were recently introduced for the treatment of arthritis because of their lower rates of gastrointestinal adverse events compared with traditional non-steroidal anti-inflammatory drugs (NSAIDs).
OBJECTIVE: To examine the medication usage patterns for both osteoarthritis (OA) and rheumatoid arthritis (RA) in Korea.
METHODS: The medical charts of a convenience sample of 402 patients with OA or RA were reviewed by the Arthritis Study Group in 14 hospitals and ten clinics in Korea.
RESULTS: Traditional oral NSAIDs were the most commonly prescribed drugs for OA (68.3%) and RA (65.1%) patients. Two-thirds (66.7%) of the RA patients taking COX-2 inhibitors were prescribed other arthritis medications concurrently and 85.1% of RA patients taking NSAIDs were prescribed other arthritis medications concurrently. Patients on NSAIDs were almost twice as likely to have a gastroprotective agent (GPA) concurrently compared to COX-2 inhibitor users (OA patients 38.1% vs 21.2%; RA patients 57.9% vs 30.6%). Overall, patients taking COX-2 inhibitors were less likely to take GPAs concurrently compared to patients not taking COX-2 inhibitors (unadjusted OR 0.36; adjusted OR 0.39).
CONCLUSIONS: Traditional oral NSAIDs were commonly prescribed to arthritis patients in Korea. In this study, patients taking COX-2 inhibitors were prescribed less adjunctive arthritis treatments and less gastroprotective agents than traditional oral NSAID users.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14606981     DOI: 10.1185/030079903125002252

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  1 in total

1.  Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.

Authors:  Eduardo Carracedo-Martínez
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.